Navigation Links
One-Third of Patients Discontinue Common Breast Cancer Therapy

PRINCETON, N.J.--(BUSINESS WIRE)--Mar 15, 2007 - An alarming study that appeared in the March 1, 2007 issue of CANCER (a peer-reviewed journal of the American Cancer Society), reports that one-third of women taking the standard five-year regimen of the hormonal breast cancer treatment tamoxifen citrate, discontinue therapy early.(1)

According to the authors, non-compliance with tamoxifen tablets is a major issue that may negatively affect treatment efficacy. While tamoxifen tablets remain a standard of care, according to these data, they are associated with compliance and persistency issues. Oncologists need to identify those at risk of non-persistence and develop strategies to combat this barrier to treatment success.

Patients at risk of non-persistence include those who prefer alternative delivery formats to traditional pills/tablets, such as liquid formulations. SOLTAMOX, the only liquid form of tamoxifen citrate, is an alternative for women who require tamoxifen therapy. SOLTAMOX may be an attractive option for women who do not like pills or cannot swallow pills. SOLTAMOX is approved by the FDA and is available in the U.S. through Cytogen Corporation. For more information about SOLTAMOX, please visit www.soltamoxus.com. -0-

WHO:   Linda Vahdat, MD, Weill Cornell Medical Center. Dr. Vahdat is a

        leading breast cancer expert and a participant in the

        Compliance Strategic Initiative -- a program designed to

        increase awareness compliance and to raise awareness

        importance of hormonal therapy in breast cancer.


WHAT:  Dr. Vahdat is available to speak with media regarding the

        importance of tamoxifen compliance and the need to offer

        patients more options.


WHEN:  March 2007


WHERE: Please contact Eliza Schleifstein (973) 387-0342 to set up a

        convenient time to interview Dr. Vahdat.

About SOLTAMOX

SOLTAMOX (tamoxifen c
'"/>




Page: 1 2 3

Related medicine technology :

1. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
2. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
3. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
4. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
5. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
6. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
9. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
10. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
11. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: One Third Patients Discontinue Common Breast Cancer Therapy
(Date:9/17/2014)... 17, 2014  The law firm McElroy, Deutsch, ... it will serve as host for "Show Me ... Risks of Healthcare Reform," a one-day conference scheduled ... systems, reimbursement, compliance and enforcement in a marketplace ... Logo -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  http://photos.prnewswire.com/prnh/20140916/146607 ...
(Date:9/17/2014)... LEIPZIG, Germany , Sept. 17, ... has entered into an exclusive technology development partnership ... imaging agents to image CD4+ positive immune T ... ImaginAb,s capability to precisely diagnose and determine therapeutic ... areas. The ability to image CD4+ T-cells will ...
(Date:9/17/2014)... , Sept. 17, 2014   GS1 US ... to implement GS1 Standards to support the 2013 ... patient safety and security in the pharmaceutical supply ... Standards to U.S. Pharmaceutical Supply Chain Business Processes ... , was developed in collaboration with GS1 ...
Breaking Medicine Technology:Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4
... TEL-AVIV, Israel , March 15, 2010 Cheetah Medical, a,worldwide leader in noninvasive hemodynamic and cardiac output ... and also included Robert,Bosch Venture Capital (RBVC), MVM Life Science Partners (MVM) and existing,investors. , ... ... ...
... With heart disease continuing to be the No. 1 cause of death in the U.S., Atherotech Inc. has ... company is expanding its disease management services with the goal of helping physicians reduce death and disability from heart disease. ... ... , ...
Cached Medicine Technology:Cheetah Medical Closes $20 Million Series B Financing 2Cheetah Medical Closes $20 Million Series B Financing 3Cheetah Medical Closes $20 Million Series B Financing 4Cheetah Medical Closes $20 Million Series B Financing 5Cheetah Medical Closes $20 Million Series B Financing 6Atherotech Recruits Top Experts in Fight Against Heart Disease 2Atherotech Recruits Top Experts in Fight Against Heart Disease 3Atherotech Recruits Top Experts in Fight Against Heart Disease 4Atherotech Recruits Top Experts in Fight Against Heart Disease 5Atherotech Recruits Top Experts in Fight Against Heart Disease 6
(Date:9/18/2014)... September 18, 2014 MD Complete ... results without a prescription, announced today that SHAPE Magazine ... the “Best Peel” in its annual Beauty Awards. ... most effective beauty products as tested by SHAPE’s expert ... real, noticeable results. Among the thousands of beauty products ...
(Date:9/18/2014)... discount dental plans website allows consumers to search ... savings in their area prior to joining the plan. Consumers ... use the plan same day. , With so many different ... be difficult. With most dental plan websites it is very ... a particular zip code before joining the plan. , That ...
(Date:9/18/2014)... 2014 With the development of ... of adjusting human body physiology, preventing diseases, promoting ... with a variety of specific populations. In 2013, ... reached RMB187.4 billion, up 12.0% year on year, ... View Full Report at http://www.marketresearchreports.biz/analysis/223449 , ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... independent freestanding emergency rooms in the United States, named ... its new Missouri City-Lakes facility. , “We are ... as facility medical director of our new Missouri City-Lakes ... of First Choice Emergency Room. , Dr. Harrison ...
(Date:9/18/2014)... 9Lover.com, an internationally well-known designer and leader ... big promotion for its maternity wedding outfits. Now, all ... discounted maternity wedding dresses on its website. ... global consumers. The company’s development manager believes the cheap ... delighted. The current special offer will last until September ...
Breaking Medicine News(10 mins):Health News:MD Complete Wins Shape Beauty Award for Best Peel 2Health News:Discount Dental Plans Allow Consumers to Search Thousands of Local Dentists, Compare Savings and Discounts, and Download a Printable Membership Card 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 3Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 4Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:Discounted Maternity Wedding Dresses For 2014 Introduced By 9Lover.com 2
... Reporter , THURSDAY, Jan. 5 (HealthDay News) -- Pediatric ... to lower the threshold for toxic lead exposure in ... and house paint, can permanently damage developing brains. ... Poisoning Prevention voted to recommend that the federal government ...
... of patients with mild-to-moderate asthma have persistently non-eosinophilic ... anti-inflammatory treatments, according to a new study. ... enrolled in nine clinical trials conducted by the ... eosinophils) was,found in only 36% of asthmatics not ...
... Mozes HealthDay Reporter , THURSDAY, Jan. 5 ... double their risk of developing a particularly advanced form ... large new European study suggests. The possible link ... (AMD), a significant cause of blindness in seniors. ...
... Proton therapy, a type of external beam radiation therapy, ... according to two new studies published in the January ... (Red Journal), the American Society for Radiation Oncology,s ... study, researchers at the University of Florida in Jacksonville, ...
... Jan. 5 (HealthDay News) -- Children and young adults ... for complications from the flu and should receive flu ... in Ohio in February 2011. Of the 130 ... young adults with neurological and neurodevelopmental conditions, 76 (58 ...
... cost paid for statins (drugs to lower cholesterol) in ... insurance is approximately 400 percent higher than comparable costs ... These findings, from the Boston University School of Medicine ... results of a comprehensive comparison of prescription drug costs ...
Cached Medicine News:Health News:Experts Endorse Lower Lead-Poisoning Threshold 2Health News:Experts Endorse Lower Lead-Poisoning Threshold 3Health News:A large subgroup of mild-to-moderate asthma is persistently non-eosinophilic 2Health News:Could Daily Aspirin Harm Seniors' Eyes? 2Health News:Could Daily Aspirin Harm Seniors' Eyes? 3Health News:Proton therapy effective prostate cancer treatment 2Health News:Study finds statin costs 400 percent higher in US compared to UK 2
... Swing doors, 8 shelves. Over-sized ... doors. Fluorescent interior lighting. Self-Contained System ... foot cord. Full One Year Warranty on ... Warranty on Compressor. Also available as ...
... Independent controls for Digital Thermostat and Digital ... steel. , Interiorwhite anodized aluminum with ... Oversized refrigeration (134A). , Temperature range ... self-closing doors. , Foamed-in-place polyurethane high ...
... The HC Series Large Capacity Refigerators ... embryos, semen, or biological samples at liquid-nitrogen ... holding times and capacities are available to ... Two low profile HCL models are also ...
... refrigerators from Taylor-Wharton are uniquely designed to ... box-type storage racks and the lower operating ... The RackSystems are available in four convenient ... 750 x 2ml vials to 4800 x ...
Medicine Products: